NOV 10, 2017 7:25 AM PST

New Generation of Antibiotics Kills Bacteria with Impeccable Precision

WRITTEN BY: Kara Marker

The only way to overcome multidrug-resistant bacteria is to design a drug that bacteria have never encountered. In a new study funded by the São Paulo Research Foundation, scientists are doing just that, with a new drug specifically designed to target bacillus bacteria.

Pseudomonas aeruginosa, Enterococcus faecalis and Staphylococcus aureus on Tryptic Soy Agar. Credit: Wikimedia User HansN

“The problem of drug-resistant bacteria is serious and hasn't been given proper attention by either governments or the pharmaceutical industry,” explained project coordinator Andréa Dessen. “We can no longer ignore it.”

Dessen and other scientists from France’s Institute of Structural Biology and Brazil’s National Bioscience Laboratory focused their efforts on new treatments for drug-resistant bacillus bacteria. Famous bacillus include Escherichia coli, Pseudomonas aeruginosa and Helicobacter pylori. Current antibiotics primarily target components unique to the bacterial cell wall, but the new approach prevents bacteria from ever building their cell wall, making each bacterial cell “not only more vulnerable but also incapable of reproducing itself.”

"The cell wall is a mesh like a fishing net, made up largely of peptidoglycan, a polymerized blend of sugars and amino acids associated with peptides," Dessen explained. "It protects the bacterium against differences in osmotic pressure and ensures the cell is the right shape.”

Bacilli bacteria contain a multiprotein complex called the elongasome that require binding of specific proteins after cell division to obtain the right shape. The elongasome was the subject of Dessen’s new study, where researchers isolated two proteins, PBP2 and MreC, to understand the complex’s three-dimensional structure using X-ray diffraction crystallography. This technology enabled researchers to observe how the two proteins interact, and, subsequently, how to prevent this interaction.

Brazilian and French scientists show that inhibiting the interaction of two key proteins for cell wall elongation can be an effective strategy to kill bacteria of the bacillus type. Image: Nature Communications

Next, researchers altered the amino acids in MreC that interact with PBP2, which prevented the two proteins from interacting and the elongasome from forming. Then, they genetically modified H. pylori bacteria to express the same mutant MreC protein, and they were subsequently unable to grow because their cell wall did not form correctly.

“The experiment proved the importance of the PBP2-MreC complex to elongation of the wall and survival of bacilli,” Dessen explained. “This knowledge can be used to seek molecules capable of interrupting the interaction between these proteins and thereby kill the bacillus."

The study’s approach, however, would be effective only against bacterial species with elongated cell walls. Most bacteria do have cell walls, but some do not - for example, an extremely deadly pathogen with acquired resistance to most available drugs, Acinetobacter baumannii. Further research will have to be completely to expand this approach to other types of bacteria.

The present study was published in the journal Nature Communications.

Source: São Paulo Research Foundation

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
NOV 25, 2020
Immunology
Another COVID-19 vaccine shows promising results!
NOV 25, 2020
Another COVID-19 vaccine shows promising results!
A week ago, another biotechnology company "Moderna" announced the preliminary results from its COVID-19 vaccin ...
NOV 24, 2020
Drug Discovery & Development
MMR Vaccine Shows Promise Against COVID-19
NOV 24, 2020
MMR Vaccine Shows Promise Against COVID-19
Researchers have found that a vaccine used for mumps, measles, and rubella (MMR) may be effective in protecting against ...
DEC 01, 2020
Immunology
Scar-Free Healing Starts With Mobilizing the Immune System
DEC 01, 2020
Scar-Free Healing Starts With Mobilizing the Immune System
Thanks to a new hydrogel biomaterial developed by researchers at Duke University, we are one step closer to the holy gra ...
JAN 27, 2021
Drug Discovery & Development
Do Vaccines Work Against New Covid Variants?
JAN 27, 2021
Do Vaccines Work Against New Covid Variants?
The SARS-CoV-2 virus is mutating faster than scientists previously thought. As such, pharmaceutical companies are now sc ...
FEB 10, 2021
Immunology
Cross-Reactive Antibodies Don't Protect Against COVID
FEB 10, 2021
Cross-Reactive Antibodies Don't Protect Against COVID
Did you know that hundreds of viruses can cause the common cold? Rhinovirus, adenovirus, and coronavirus infections can ...
Loading Comments...